Immunome director awarded options for 9,897 shares

Immunome Inc. director Jean Jacques Bienaimé received a new stock option grant covering 9,897 shares of common stock.

Rhea-AI Filing Summary

Immunome Inc. director Jean Jacques Bienaimé received a new stock option grant covering 9,897 shares of common stock. The option has an exercise price of $18.16 per share and expires on June 9, 2036. Following this grant, he holds options for 9,897 shares directly.

The option vests in four equal quarterly installments, beginning on June 10, 2026 and continuing on the same day of each succeeding fiscal quarter for one year, subject to his continued service with the company on each vesting date.

Insider Trade Summary

Grant/Award: 9,897 shares

Grant/Award 1 txn

Insider BIENAIME JEAN JACQUES

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	9,897	$0.00	$0.00

Holdings After Transaction: Director Stock Option (right to buy) — 9,897 contracts (Direct)

Footnotes (1)

1. F1. The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.

Key Figures

Option grant size: 9,897 shares Exercise price: $18.16 per share Post-grant options held: 9,897 options +3 more

6 metrics

Option grant size 9,897 shares Director stock option underlying common shares

Exercise price $18.16 per share Director stock option strike price

Post-grant options held 9,897 options Total derivative securities following transaction

Expiration date June 9, 2036 Option term end date

Vesting start date June 10, 2026 First quarterly vesting installment

Vesting schedule length Four quarterly installments Over one year, subject to continuous service

Key Terms

Director Stock Option (right to buy), underlying security, exercise price, vesting, +1 more

5 terms

Director Stock Option (right to buy) financial

"security_title: Director Stock Option (right to buy)"

underlying security financial

"underlying_security_title: Common Stock; underlying_security_shares: 9897.0000"

exercise price financial

"conversion_or_exercise_price: 18.1600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option vests in four equal quarterly installments, commencing from June 10, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-06-09T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Immunome (IMNM) report for Jean Jacques Bienaimé?

Immunome reported a stock option grant to director Jean Jacques Bienaimé for 9,897 shares of common stock. This compensation-related award gives him the right to buy shares at a fixed exercise price if vesting and service conditions are met.

How many Immunome (IMNM) shares are covered by the new option grant?

The new option grant covers 9,897 shares of Immunome common stock. These are underlying shares that may be purchased if the option vests and is exercised, providing potential future equity exposure rather than an immediate share purchase.

What is the exercise price and expiration date of Jean Jacques Bienaimé’s Immunome (IMNM) options?

The option has an exercise price of $18.16 per share and expires on June 9, 2036. This means he can buy shares at $18.16, if vested, any time before the option’s expiration date, subject to plan terms.

How do the Immunome (IMNM) director options for Jean Jacques Bienaimé vest?

The option vests in four equal quarterly installments starting June 10, 2026. Vesting continues on the same day of each succeeding fiscal quarter for one year, and each installment requires his continuous service with Immunome on the applicable vesting date.

Is the Immunome (IMNM) Form 4 transaction an open-market buy or a compensation grant?

The Form 4 reflects a compensation grant, not an open-market share purchase. Jean Jacques Bienaimé received a director stock option award with no cash price per option at grant, classified as a grant or award acquisition by the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 05:54 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BIENAIME JEAN JACQUES

(Last) (First) (Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$18.16	06/10/2026		A		9,897		(1)	06/09/2036	Common Stock	9,897	$0	9,897	D

Explanation of Responses:

1. The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.

	/s/ Sandra Stoneman, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)